The U.S. Supreme Court refused to accept the patent dispute ...

The U.S. Supreme Court refused to accept the patent dispute between Sandoz and Amgen about its anti-inflammatory blockbuster Enbrel. A few days ago, Amgen repelled a second potential competitor and ensured that the launch of Samsung's Enbrel biosimilar drug was postponed to 2029.

According to the latest verdict, the U.S. District Court of New Jersey supports the claims of Amgen, Roche, and Immunex, requiring Samsung Bioepis’ Enbrel biosimilar Eticovo not to enter the U.S. market before 2029. $Amgen (AMGN.US)$ $Gilead Sciences (GILD.US)$